Its clinical course, immunological features, imaging findings, and response to treatment are different from anti-aquaporin-4 (AQP4) antibody seropositive neuromyelitis optica spectrum disorders (NMOSD) and classical multiple sclerosis (MS). This evidence concerns the gene AQP4 and myeloid sarcoma.